Screener
Inhibikase Therapeutics, Inc. IKT Q1 2026 earnings
Reported May 12, 2026 · Before market open
EPS-$0.10In line
EPS estimate-$0.10
Next report
Nov 13, 2026 (in 2 months)EPS estimate-$0.11
Versus estimates
Diluted EPS
FAQ
- When did Inhibikase Therapeutics, Inc. report Q1 2026 earnings?
- Inhibikase Therapeutics, Inc. (IKT) reported Q1 2026 earnings on May 12, 2026 before market open.
- What were Inhibikase Therapeutics, Inc.'s Q1 2026 revenue and EPS?
- Inhibikase Therapeutics, Inc. reported eps of $-0.10 for Q1 2026.
- Did Inhibikase Therapeutics, Inc. beat estimates in Q1 2026?
- EPS beat the consensus estimate of $-0.10 by $0.00.
- How did Inhibikase Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 33.3% from $-0.15.
- Where can I find Inhibikase Therapeutics, Inc.'s Q1 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-219610) and the 10-Q periodic report (0001193125-26-219641) directly on SEC EDGAR. The filing index links above go to sec.gov.
